Overview of serotonin 1A receptor selective agents in anxiety disorders-the developmental situation in Japan

References

• Asoh T., Nakajima K., Uchiumi M., et al. The effects of buspirone on actual driving performance. Japanese Journal of Neuropsychopharmacology 1993; 15: 465–473
   Google Scholar
• Barrett J.E., Witkin J.M. Buspirone in animal models of anxiety. Buspirone-Mechanisms and clinical Aspects, G. Tunicliff, A.S. Eison, D.P. Taylor. Academic Press, San Diego 1991; 37–79
   Google Scholar
• Berger F.M. Anxiety and the discovery of the tranqulizers. Discoveries in Biological Psychiatry, F.J. Ayd, B. Blackwell. Lippincott, Philadelphia 1970; 115–119
   Google Scholar
• Borison R.L., Albrecht J.W., Diamond B.I. Efficacy and safety of a putative anxiolytic agent:ipsapirone. Psychopharmacological Bulletin 1990; 26: 207–210
   PubMedGoogle Scholar
• Bover W.F., Feighner J.P. A placebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorder. International Clinical Psychopharmacology 1993; 8: 173–176
   Google Scholar
• Chojnacka-Wojcik E., Przegaunski E. Evidence for the involvement of 5-HT1A receptors in the anriconflict effects of ipsapirone in rats. Neuropharmacology 1991; 30: 707–709
   Google Scholar
• Dompert W.U., Glaser T., Traber J. 3H-TVX Q 7821: identification of 5-HT1A binding sites as target for a novel putative anxiolytic. Naunyn-Schmiedeberg's Archives of Pharmacology 1985; 328: 367–470
   Google Scholar
• Eison M.S. Azapirones: Clinical uses of serotonin partial agonists. Family Practice Recertification 1989; 11: 8–16, Suppl
   Google Scholar
• Eison A.S., Eison M.S., Stanley M., et al. Serotonergic mechanisms in the behavioral effects of buspirone and gepirone. Pharmacology Biochemistry and Behaviour 1986; 24: 25–32
   Google Scholar
• Eison A.S., Temple D. L., Jr. Buspirone: Review of its pharmacology and current perspectives on its mechanism of action. American Journal of Medicine 1986; 80(Suppl. 3B)1–9
   PubMedGoogle Scholar
• Geller I., Hartmann R.J. Effects of buspirone on operant behavior of laboratory rats and cynomologus monkeys. Journal of Clinical Psychiatry 1982; 43: 25–32
   PubMed Web of Science ®Google Scholar
• Glaser T. Ipsapirone, a potent and selective 5-HT1A receptor ligand with anxiolytic and antidepressant properties. Drugs Future 1988; 13: 429–439
   Google Scholar
• Goa K.L., Ward A. Buspirone. Drugs 1986; 32(32)114–129
   Google Scholar
• Hjorth S., Carlsson A. Buspirone: effects on central monoaminergic transmission—possible relevance to animal experimental and clinical findings. European Journal of Pharmacology 1982; 83(83)299–303
   Google Scholar
• Howard J.L., Pollard G.T. Effects of buspirone in geller-Seifter test with incremental shock. Drug Development, & Research 1990; 19: 37–49
   Google Scholar
• Kimura M., Sakata T., Nakagawa T., et al. Clinical evaluation of tandospirone (SM-3997) on psychosomatic diseases with gastrointestinal complaints—a comparative double-blind controlled study with diazepam and placebo. Clinical Evaluation 1992; 20: 225–257, in Japanese
   Google Scholar
• Kudo Y., Nakajima T., Sakai T., et al. Clinical evaluation a new nonbenzo-diazepine anxiolytic drug, buspirone, on neurosis. Japanese Journal of Clinical Psychiatry 1989; 18: 1460–1471, in Japanese
   Google Scholar
• Kudo Y., Sakai T., Hayashi M., et al. A clinical study of ipsapirone hydrochloride (BAY q 7821) on various types of neurosis—an early phase 2 study in Kansai area. Journal of Clinical Therapeutic Medicine 1994; 10: 2003–2021, in Japanese
   Google Scholar
• Kurihara M., Itoh H., Murasaki M., et al. Clinical evaluation of antianxiety drug, buspirone, on various neurosis—early phase 2 study in Tokyo area. Japanese Pharmacological Therapeutics 1989; 17: 4989–5007, in Japanese
   Google Scholar
• Kurihara M., Murasaki M., Endo S., et al. Efficacy of a new anxiolytic buspirone, on neurosis—a comparative double-blind study with diazepam and placebo. Clinical Evaluation 1990; 18: 433–454, in Japanese
   Google Scholar
• Lader M. Dependence of benzodiazepines. Journal of Clinical Psychiatry 1983; 44: 121–127
   PubMed Web of Science ®Google Scholar
• Miura S., Asai M., Itoh K., et al. Clinical study of buspirone on neurosis—a comparative double-blind trial with placebo. Clinical Evaluation 1992; 19: 447–475, in Japanese
   Google Scholar
• Murasaki M. Non-benzodiazepine anxiolytics. Japanese Journal of Psychiatric Treatment 1990; 5: 25–43, in Japanese
   Google Scholar
• Murasaki M., Miura S. The future of 5-HT1A receptor agonists. Progressive Neuro-Psychopharmacological and Biological Psychiatry 1992; 16: 833–845
   Google Scholar
• Murasaki M., Mori A., Endo S., et al. Late phase 2 study of a new anxiolytic SM-3997 (tandospirone) on neurosis. Clinical Evaluation 1992a; 20: 259–293, in Japanese
   Google Scholar
• Murasaki M., Mori A., Hasegawa K., et al. Clinical evaluation of anti-anxiety drug, SM-3997 (tandospirone), on neurosis—early phase 2 study at Tokyo area. Clinical Report 1992b; 26: 4203–4216, in Japanese
   Google Scholar
• Murasaki M., Mori A., Endo S., et al. Efficacy of a new anxiolytic, tandospirone (SM-3997) on neurosis—a comparative double-blind study with diazepam. Clinical Evaluation 1992c; 20: 295–329, in Japanese
   Google Scholar
• Murasaki M., Miura S., Kamijima K., et al. Efficacy of ipsapirone hydrochloride on anxiety neurosis—an early phase 2 study in Kanto area (in Japanese). Journal of Clinical Therapeutic Medicine
   Google Scholar
• Murasaki M., Miura S., Yamashtta I., et al. A dose finding study of BAY q 7821 (ipsapirone hydrochloride) on neurosis—a double-blind, three group comparative study (in Japanese). Clinical Evaluation
   Google Scholar
• Nishizono M. Therapeutic efficacy of new anti-anxiety drug, buspirone, on neurosis. Clinical Psychiatry 1988; 30: 803–811, in Japanese
   Google Scholar
• Nishizono M. Drug evaluation of buspirone on various neurosis; a comparative double-blind study with bromazepam. Clinical Psychiatry 1991; 33: 985–999, in Japanese
   Google Scholar
• Okada H., Asano Y., Itoh K., et al. Therapeutic efficacy of a new anti-anxiety drug, buspirone, on neurosis. Clinical Psychiatry 1988; 30: 803–811, in Japanese
   Google Scholar
• Okada H., Asano Y., Itoh K., et al. Clinical evaluation of a new anxiolytic, buspirone—a comparative double-blind study with diazepam. Journal of Clinical and Experimental Medicine (Igaku no Ayumi) 1991; 156: 747–769, in Japanese
   Google Scholar
• Rickels K. Buspirone in Clinical practice. Journal of Clinical Psychiatry 1990; 51(Suppl 9)51–54
   Google Scholar
• Rickels K., Case G.W., Schweizer E.E., et al. Low-dose dependence in chronic benzidiazepine users: a preliminary report on 110 patients. Psychopharmacological Bulletin 1986; 22: 403–415
   Google Scholar
• Rickels K., Schweizer E., Csanalosi I., et al. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Archives of General Psychiatry 1988; 45: 444–450
   PubMed Web of Science ®Google Scholar
• Robinson D.S. Clinical profile of buspirone. Buspirone-Mechanisms and Clinical Aspects, G. Tunnicliff, A.S. Eison, D.P. Taylor. Academic Press, San Diego 1991; 37–79
   Google Scholar
• Schreiber R., de Vry J. Neuro-anatomical correlate of the anxiolytic effects of the 5-HT1A receptor ligands 8-OH-OPAT, ipsapirone and buspirone in rat. Psychopharmacology 1990; 101: 52
   Google Scholar
• Shimizu H., Hirose A., Tatsuno T., et al. Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate. Japanese Journal of Pharmacology 1987; 45: 493–500
   Google Scholar
• Shimizu H., Karai N., Hirose A., et al. Interaction of SM-3997 with serotonin receptors in rat brain. Japanese Journal of Pharmacology 1988; 46: 311–314
   Google Scholar
• Shimizu H., Tatsuno T., Hirose A., et al. Serotonergic mechanisms in anxiolytic effect of tandospirone in the Vogel conflict test. Japanese Journal of Pharmacology 1992; 59: 105–112
   PubMedGoogle Scholar
• Sternbach I.H. Benzodiazepine story. Journal of Medical Chemistry 1979; 22: 1–7
   PubMed Web of Science ®Google Scholar
• Traber W.U., Glaser T. 5-HT1A receptor-related anxiolytics. Trends in Pharmacological Science 1987; 8: 432–433
   Web of Science ®Google Scholar
• Nishizono S., Saito T., Katsura T., et al. Clinical evaluation of tandospirone (SM-3997) on neurosis—placebo-controlled dose-finding study. Clinical Reports 1992; 26: 4265–4288, in Japanese
   Google Scholar
• Tunnicliff G., Eison A.S. Clinical pharmacology of buspirone action. Buspirone-Mechanisms and Clinical Aspects, G. Tunnicliff, A.S. Eison, D.P. Taylor. Academic Press, San Diego 1991; 19–34
   Google Scholar
• Uchiumi M., Suzuki M., Ishigooka J., et al. The effects of buspirone, an aryl-piperazine derivative, and bromazepam, a benzodiazepine derivative on daytime sleepiness. Japanese Journal of Neuropsychopharmacology 1993; 15: 441–452, in Japanese
   Google Scholar
• Wettstein J.M. Behavioral effects of acute and chronic buspirone. European Journal of Pharmacology 1988; 151: 341–344
   Google Scholar